Skip to main content

EAGD T-cell

Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide

  • RegistryNCT03533816
  • PhasePhase 1
  • StatusRecruiting
  • ConditionAcute Myeloid Leukemia
  • SponsorUniversity of Kansas Medical Center
How EAGD T-cell worksNCT035338161 min

What the film says

Read the transcript

For many leukemias, a bone marrow transplant is the only cure: the donor's immune cells finish the leukemia. The same cells can also attack the patient, called graft-versus-host disease, and with a half-matched donor the risk climbs.

The idea: keep the cells that kill leukemia, and leave behind those that start the war.

Most T cells are the alpha-beta kind, which cause graft-versus-host disease. A small minority, gamma-delta T cells, recognize cancer cells directly, without the matching that triggers attacks on healthy tissue. From the donor's blood, those cells are pulled out, multiplied, and infused after transplant.

At Kansas and Ohio State, with Joseph McGuirk, the trial asks whether that is safe, and whether relapse and graft-versus-host disease drop. Public record; not medical advice.

Sources behind this film

  • ClinicalTrials.gov record NCT03533816

    Transplant as the only cure for many leukemias; donor cells finish the leukemia; GVHD risk climbs with a half-matched donor; Alpha-beta T cells drive GVHD; gamma-delta T cells kill malignant cells without antigen recognition; Donor blood, expanded and activated, alpha-beta depleted, infused after transplant at 1, 3, or 10 million cells/kg; Kansas and Ohio State; Joseph McGuirk; safety, GVHD rate

The drug

What is being tested.

The Alpha Beta (α/β) T-Cell Depletion System utilizes the CliniMACS instrument to yield a gamma delta (γδ) enriched cell therapy product.

Many patients with hematological malignancies require a bone marrow transplant for curative treatment. A matched sibling donor is optimal but may not be available. Therefore, a partially matched family member (haploidentical) may be a viable alternative. The incidence of graft vs. host disease, however, can become more of a significant, even fatal, factor with partial matches. T-cells have been shown to be the key player in the post-transplant immune phenomena.

The majority of T-cells are composed of alpha beta T-cells with a small minority of gamma delta T-cells, which are known to have the unique ability to kill malignant cells without antigen recognition. This study proposes to extract, concentrate, and activate gamma delta T-cells from the peripheral blood to provide innate anti-tumor effect with minimal risk of GVHD. Safety and impact and/or the rate of GVHD will be evaluated.

The study

How the trial runs.

Gamma delta T-cells are part of the innate immune system with the ability to recognize malignant cells and kill them. This study uses gamma delta T-cells to maximize the anti-tumor response and minimize graft versus host disease (GVHD) in leukemic and myelodysplastic patients who have had a partially mismatched bone marrow transplant (haploidentical).

Live record on ClinicalTrials.gov →

Eligibility

Who the study is looking for.

  • The following criteria are used to enroll patients in the study before transplant.
  • Patients with neoplastic hematological disorders with indication of allogeneic transplant according to the National Comprehensive Cancer Network (NCCN) or other standard guidelines as follows:
  • Acute myeloid leukemia [AML] in morphologic complete remission with intermediate/high-risk features (per NCCN criteria) or relapsed disease
  • Chronic myeloid leukemia [CML] in any chronic phase.
  • Myelodysplastic syndrome [MDS] with intermediate/high risk features or refractory disease (with bone marrow blast count <10%).
  • Acute lymphoblastic leukemia [ALL] in morphologic complete remission with high-risk features or relapsed disease.

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.

For you, or someone you love

Whether or not this trial is the one, bring AI into your corner.

A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.

  • Read in plain words

    Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.

  • Ready for every appointment

    Ask about your own file, and walk in with questions for your oncologist or the trial team.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.

Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.

How these trials work: what Phase 1 actually is · common questions Not clinical evidence.